Our scientists have found a way to rein in a cancer-causing gene called MYCN and slow down the growth of the childhood cancer neuroblastoma.
Our researchers have used a tiny drug delivery vehicle to kill neuroblastoma cells without harming normal tissues.
If doctors can reliably tell which children are most likely to get their leukaemia back, they can offer more intensive treatment options to prevent it.
Blood vessels supply the fuel needed for rapid tumour growth and spread. But what happens when the network is disrupted?
Our latest research is providing ammunition to target the rare but aggressive MLLr leukaemia subtype.
A surprising discovery transforms our thinking about one of the ‘universal features’ of cancer.
A previously unknown subgroup of high-risk leukaemia in children has been revealed with a new, more accurate DNA test.
By looking at DNA-packing proteins, we identified a new drug target for neuroblastoma called DOT1L. See how we joined the dots.
A test that makes drug-resistant leukaemia cells glow could reveal a brighter future for developing new leukaemia therapies.
A study published this month shows venetoclax could successfully target high-risk leukaemia subtypes in infants or children. Clinical trials are planned.